Literature DB >> 12776000

Serotonin and its implication for the management of irritable bowel syndrome.

Michael D Gershon1.   

Abstract

Our understanding of the enteric nervous system (ENS) has evolved from the "classical" view, in which the brain controls all enteric behavior, to the current view, which holds that enteric innervation is one of local control within the bowel, modified by a bidirectional "dialogue" with the brain. The ENS independently controls enteric reflexes through intrinsic primary afferent neurons, which monitor intraluminal conditions. This monitoring is accomplished through the use of enteroendocrine cells in the mucosa, the best known of which are the serotonin-containing enterochromaffin cells. This article describes the roles that serotonin, specific serotonin-receptor subtypes, and the serotonin reuptake transporter play in the ENS and in the communication between the ENS and central nervous system. The way in which these findings have implicated serotonin in irritable bowel syndrome is discussed.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12776000

Source DB:  PubMed          Journal:  Rev Gastroenterol Disord        ISSN: 1533-001X


  26 in total

1.  Serotonin receptor diversity in the human colon: Expression of serotonin type 3 receptor subunits 5-HT3C, 5-HT3D, and 5-HT3E.

Authors:  Johannes Kapeller; Dorothee Möller; Felix Lasitschka; Frank Autschbach; Ruud Hovius; Gudrun Rappold; Michael Brüss; Michael D Gershon; Beate Niesler
Journal:  J Comp Neurol       Date:  2011-02-15       Impact factor: 3.215

Review 2.  Muscarinic receptors: their distribution and function in body systems, and the implications for treating overactive bladder.

Authors:  Paul Abrams; Karl-Erik Andersson; Jerry J Buccafusco; Christopher Chapple; William Chet de Groat; Alison D Fryer; Gary Kay; Alan Laties; Neil M Nathanson; Pankaj Jay Pasricha; Alan J Wein
Journal:  Br J Pharmacol       Date:  2006-06-05       Impact factor: 8.739

Review 3.  Weaving single photon imaging into new drug development.

Authors:  P David Mozley
Journal:  Mol Imaging Biol       Date:  2005 Jan-Feb       Impact factor: 3.488

4.  Serotonin activates dendritic cell function in the context of gut inflammation.

Authors:  Nan Li; Jean-Eric Ghia; Huaqing Wang; Jessica McClemens; Francine Cote; Youko Suehiro; Jacques Mallet; Waliul I Khan
Journal:  Am J Pathol       Date:  2011-02       Impact factor: 4.307

Review 5.  Symptom overlap and comorbidity of irritable bowel syndrome with other conditions.

Authors:  Christine L Frissora; Kenneth L Koch
Journal:  Curr Gastroenterol Rep       Date:  2005-08

Review 6.  IBS--review and what's new.

Authors:  Amy Foxx-Orenstein
Journal:  MedGenMed       Date:  2006-07-26

Review 7.  [Drug therapy for irritable bowel syndrome. What works, what doesn't work and for whom?].

Authors:  H Mönnikes; M Schmidtmann; I R van der Voort
Journal:  Internist (Berl)       Date:  2006-10       Impact factor: 0.743

8.  Association of Serotonin Transporter Promoter Polymorphism (5-HTTLPR) with Microscopic Colitis and Ulcerative Colitis.

Authors:  Arbab Sikander; Saroj Kant Sinha; Kaushal Kishor Prasad; Satya Vati Rana
Journal:  Dig Dis Sci       Date:  2014-12-23       Impact factor: 3.199

9.  Long-term tegaserod treatment for dysmotility-like functional dyspepsia: results of two identical 1-year cohort studies.

Authors:  William D Chey; Colin W Howden; Jan Tack; Gregory Ligozio; David L Earnest
Journal:  Dig Dis Sci       Date:  2009-12-03       Impact factor: 3.199

Review 10.  Serotonin receptors and their role in the pathophysiology and therapy of irritable bowel syndrome.

Authors:  C Stasi; M Bellini; G Bassotti; C Blandizzi; S Milani
Journal:  Tech Coloproctol       Date:  2014-01-15       Impact factor: 3.781

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.